389PRisk factors of nivolumab-induced pneumonitis in patients with solid tumors

Background: Nivolumab is an anti-programmed death 1 (PD-1) monoclonal antibody, which has demonstrated antitumor efficacy in clinical trials of various malignant tumors. Pneumonitis is a common adverse event in patients treated with nivolumab. However, the difference of the frequency and severity of nivolumab-induced pneumonitis across different tumor types is not clear.

https://ift.tt/2PYaGSz